Sarepta Therapeutics, Inc.

SRPT

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
SRPT
CIK0000873303
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142
Website sarepta.com
Phone617-274-4000
CEODouglas S. Ingram
Employees840

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$2.48 billion
Pre-Tax Income$-24.13 million
Net Income$-57.96 million
Net Income to Common$-57.96 million
EPS$-0.81
View All
Balance Sheet
Cash$510.60 million
Assets$3.68 billion
Liabilities$2.32 billion
Common Equity$1.36 billion
Liabilities & Equity$3.68 billion
View All
Cash Flow Statement
Calculations
NOPAT$-652,400.00
EBITDA$16.95 million
Price to EarningsN/A
Price to Book$1.32
ROE-4.76%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Why Elanco (ELAN) Stock Is Trading Up Today

Shares of animal health company Elanco (NYSE:ELAN) jumped 4.4% in the morning session after the company announced it will be joining the S&P MidCap 400 index.

Article Link

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

Health care stocks were mixed premarket Wednesday, as the Health Care Select Sector SPDR Fund (XLV)

Article Link

Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (XNYS: BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will re

Article Link

Sarepta Therapeutics (SRPT): Assessing Valuation After Lawsuits and FDA Scrutiny Over ELEVIDYS Safety Concerns

If you have been watching Sarepta Therapeutics (SRPT), this week's headlines have probably caught your eye. Multiple law firms have announced class action lawsuits against the company, following claims that Sarepta misrepresented or concealed serious safety issues tied to its ELEVIDYS gene therapy. These allegations include undisclosed patient deaths, halted clinical trials, and FDA scrutiny, making this much more than legal noise. For investors, the lawsuits and their underlying cause raise...

Article Link

Credit Fuels the AI Boom — and Fears of a Bubble

JPMorgan Chase & Co. and Mitsubishi UFJ Financial Group are leading the sale of a more than $22 billion loan to support Vantage Data Centers’ plan to build a massive data-center campus, people with knowledge of the matter said this week. Meta Platforms Inc., the parent of Facebook, is getting $29 billion from Pacific Investment Management Co. and Blue Owl Capital Inc. for a massive data center in rural Louisiana, Bloomberg reported this month.

Article Link